Skip to search formSkip to main contentSkip to account menu

Recombinant Adenovirus 5 Encoding Tumor Necrosis Factor-related Apoptosis-Inducing Ligand

Known as: Ad5-TNFSF10, Ad5-TRAIL 
An adenovirus type 5 (Ad5) encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), with potential apoptosis-inducing and… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma
Abstract Tumor progression occurs through the modulation of a number of physiological parameters, including the development of… 
2014
2014
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells
It is now appreciated that there are distinct subsets of dendritic cells (DC) with specialized functions. Plasmacytoid DC (pDC… 
2014
2014
Mechanisms of action for Ad5-TRAIL/CpG immunotherapy for the treatment of advanced renal cell carcinoma
University of Minnesota Ph.D. dissertation. June 2014. Major:Microbiology, Immunology and Cancer Biology. Advisor: Thomas S… 
2010
2010
Assessment of CAR- or CD46-Dependent Adenoviral Vector-Mediated TRAIL Gene Therapy in Clinical Adenocarcinoma Lung Cancer Cells
Adenoviral vector-mediated transfer of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can be a powerful approach… 
Highly Cited
2007
Highly Cited
2007
Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
CD8(+) T-cell activation via cross-presentation of antigens from apoptotic tumor cells is controversial. Dendritic cells capture… 
2007
2007
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity
Interest in TNF-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic has been high since its first description… 
2007
2007
Phase I study of Ad5-TRAIL in men with clinically organ confined prostate cancer
AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 4870 We have developed a recombinant adenovirus that encodes human TNF… 
2006
2006
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors
Renal cell carcinoma (RCC) will cause greater than 12 000 deaths in the United States this year. The lack of effective therapy… 
Highly Cited
2005
Highly Cited
2005
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Highly Cited
2001
Highly Cited
2001
Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus.
TRAIL is a member of the tumor necrosis factor superfamily that induces apoptosis in a variety of tumor cell types both in vitro… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)